Absence of mgrB Alleviates Negative Growth Effects of Colistin Resistance in Enterobacter cloacae

Jessie E Wozniak; Aroon T Chande; Eileen M Burd; Victor I Band; Sarah W Satola; Monica M Farley; Jesse T Jacob; I King Jordan; David S Weiss

doi:10.3390/antibiotics9110825

Absence of mgrB Alleviates Negative Growth Effects of Colistin Resistance in Enterobacter cloacae

Antibiotics (Basel). 2020 Nov 19;9(11):825. doi: 10.3390/antibiotics9110825.

Authors

Jessie E Wozniak^{1

2

3}, Aroon T Chande^{4

5

6

7}, Eileen M Burd^{2

3}, Victor I Band^{1

2

3}, Sarah W Satola^{2

3}, Monica M Farley^{2

3

8}, Jesse T Jacob^{2

3}, I King Jordan^{5

9}, David S Weiss^{1

2

3

8}

Affiliations

¹ Emory Vaccine Center, Atlanta, GA 30317, USA.
² School of Medicine, Emory University, Atlanta, GA 30322, USA.
³ Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA.
⁴ Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.
⁵ School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.
⁶ Applied Bioinformatics Laboratory, Atlanta, GA 30346, USA.
⁷ PanAmerican Bioinformatics Institute, Cali 760043, Valle del Cauca, Colombia.
⁸ Atlanta VA Medical Center, Decatur, GA 30033, USA.
⁹ IHRC Applied Bioinformatics Laboratory, Georgia Institute of Technology, Atlanta, GA 30332, USA.

Abstract

Colistin is an important last-line antibiotic to treat highly resistant Enterobacter infections. Resistance to colistin has emerged among clinical isolates but has been associated with a significant growth defect. Here, we describe a clinical Enterobacter isolate with a deletion of mgrB, a regulator of colistin resistance, leading to high-level resistance in the absence of a growth defect. The identification of a path to resistance unrestrained by growth defects suggests colistin resistance could become more common in Enterobacter.

Keywords: CRE; Enterobacter; colistin.

Abstract

Grants and funding